AbbVie (NYSE:ABBV) stock stays in focus as Skyrizi and Rinvoq growth offsets Humira erosion, lifting Q1 Revenue, EPS guidance and investor attention on ABBV.

Key Highlights

  • AbbVie reported Q1 2026 revenue of $15 billion, up 12.4% year over year.
  • Skyrizi revenue reached $4.48 billion, Rinvoq reached $2.12 billion, while Humira fell to $688 million.
  • AbbVie raised full-year 2026 adjusted EPS guidance to $14.08-$14.28.

AbbVie Inc. (NYSE:ABBV) remains one of the most-watched US large-cap pharmaceutical stocks after a Q1 2026 Earnings print that confirmed the company's post-Humira transition is delivering. With a market Capitalization of about $371.72 billion, ABBV continues to lead in immunology. Shares slipped 0.18% on the snapshot day.

Why the Stock Is in Focus Today

AbbVie reported Q1 2026 revenue of $15 billion, up 12.4% year over year, beating internal projections of $14.7 billion. Adjusted EPS was $2.65 versus the $2.59 consensus. Skyrizi global net revenues reached $4.48 billion (up 30.9% reported), Rinvoq reached $2.12 billion (up 23.3%), while Humira fell 38.6% to $688 million. AbbVie raised full-year 2026 adjusted EPS guidance to $14.08-$14.28 from $13.96-$14.16 and now expects Skyrizi revenues of ~$21.6 billion and Rinvoq revenues of ~$10.2 billion in 2026.

Latest Share Price Movement

ABBV traded at $210.39, down 0.18% on the day, with Volume of 5.36 million shares and a relative volume reading of 0.94. The stock jumped more than 3% post-earnings on April 29.

Key News Driving Investor Attention

Three news items shape investor attention. First, Skyrizi and Rinvoq combined revenues exceeded peak Humira sales for the first time, validating the immunology pipeline pivot. Second, the EPS guide raise. Third, FDA filings: a new application for Rinvoq in severe alopecia areata and Skyrizi subcutaneous induction in Crohn's disease.

Earnings and Financial Performance

Diluted EPS on a trailing-twelve-month basis stands at $2.03 with EPS growth of -13.55% year over year. The TTM headline reflects ongoing Humira biosimilar erosion, partly offset by Skyrizi and Rinvoq momentum.

Sector Outlook

The US large-cap pharmaceutical sector continues to navigate biosimilar competition for legacy Biologics, IRA pricing negotiations, and the GLP-1 reshaping of overall pharma sales mix.

Risks Investors Are Watching

Risks include Humira biosimilar erosion, Inflation Reduction Act price negotiations for select products, competitive intensity in the immunology space, and pipeline execution.

What to Watch Next

Catalysts ahead include the Q2 2026 print, Skyrizi/Rinvoq label expansions, oncology pipeline updates and any new bolt-on acquisitions.

Conclusion

AbbVie’s Q1 2026 results show that the post-Humira transition is gaining traction, with Skyrizi and Rinvoq now driving the immunology growth profile. The guidance raise reinforces management’s confidence, while recent FDA filings add pipeline optionality. However, Humira biosimilar erosion, pricing pressure under the Inflation Reduction Act and competition in immunology remain material risks. ABBV’s next test will be whether Skyrizi, Rinvoq and pipeline Assets can sustain growth through the next earnings cycle.